Get the Stockscreener App
31.41
4.38%
-1.44
After Hours:
31.21
-0.20
-0.64%
Cue Biopharma Inc stock is traded at $31.41, with a volume of 228.13K.
It is down -4.38% in the last 24 hours and up +17.38% over the past month.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
See More
Previous Close:
$32.85
Open:
$33.12
24h Volume:
228.13K
Relative Volume:
0.92
Market Cap:
$228.18M
Revenue:
$32.73M
Net Income/Loss:
$-19.52M
P/E Ratio:
-5.6825
EPS:
-5.5275
Net Cash Flow:
$-24.61M
1W Performance:
-15.22%
1M Performance:
+17.38%
6M Performance:
+296.29%
1Y Performance:
+51.72%
1-Day Range:
$30.75
$33.40
1-Week Range:
$23.80
$41.50
52-Week Range:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
31.41 | 228.18M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? - Insider Monkey
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CUE) 2026-09-24 - Seeking Alpha
Cue Biopharma (CUE) Short Interest & Short Float | Updated Sep 2026 $CUE - MarketBeat
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer - GlobeNewswire Inc.
China syndrome? Phase II wins for Cue in CSU, stock melts down - BioWorld News
Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking - AD HOC NEWS
Cue Biopharma rated Buy after positive phase 2 results show superior efficacy in treating chronic spontaneous urticaria. - Pluang
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA - Seeking Alpha
B. Riley's Buy Rating on Cue Biopharma (CUE) Highlights Market's High Price-to-Sales Expectations - GuruFocus
Cue Biopharma Announces Positive Phase 2 Results for CUE-221 in Chronic Spontaneous Urticaria - Kalkine Media
Cue Biopharma (CUE) Shares Drop 31% After Phase 2 Trial Results Despite Promising Efficacy - GuruFocus
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset - Seeking Alpha
What's Going on With Cue Biopharma Stock on Monday? - Benzinga
Cue Biopharma (CUE) Surges 41.7% Pre-Market Amid Market Rally an - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Cue Biopharma reports positive Phase 2 topline results for CUE-221 in CSU, durable benefit vs placebo and omalizumab - TradingView
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results - Yahoo Finance
Why is Cue Biopharma stock surging today? By Investing.com - Investing.com Canada
Cue Biopharma, Inc.(NasdaqCM: CUE) added to S&P Global BMI Index - marketscreener.com
Cue Biopharma (CUE) Reports Positive Phase 2 Data, Market Pricin - GuruFocus
Cue Biopharma reports positive phase 2 results for CUE-221 By Investing.com - Investing.com Canada
Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria - quiverquant.com
Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria - TradingView
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) - Eastern Progress
Cue Biopharma (CUE) Stock Gains on B. Riley Buy Rating Amid High P/S Valuation - gurufocus.com
Cue Biopharma is a new Buy at B. Riley on valuation - TradingView
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
CUE Initiated Coverage On by B. Riley Securities -- Price Target $83.00 - GuruFocus
Cue Biopharma Price Target Announced at $83.00/Share by B. Riley Securities - Moomoo
Cue Biopharma stock initiated at Buy by B.Riley on allergy drug potential - Investing.com Nigeria
Enterprise value to EBIT forward of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma (CUE) Slides 8.21% to $28.00, Testing Support Near $26.60Volatility Skew - dars.gov.et
Cue Biopharma Inc (CUE) Financials FY2025: Revenue $27.5M, Net Loss $26.6M - Stock Titan
Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake - TradingView
Cue Biopharma (CUE) CEO builds stake with stock awards and cheap warrants - Stock Titan
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Driehaus Capital Management Acquires New Stake in Cue Biopharma Inc (CUE) - GuruFocus
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock - Investing.com
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock By Investing.com - Investing.com South Africa
Cue Biopharma legal chief sells $265,627 in common stock - Investing.com
Cue Biopharma legal chief sells $265,627 in common stock By Investing.com - Investing.com Canada
Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock - MarketBeat
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
Cue Biopharma (CUE) Leaps 10.04% to $34.2, Testing Key Resistance at $35.91Seasonality Effect - Vinanet
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - manilatimes.net
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Canada
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):